OriGen Biomedical, Inc.
Classification
Private
About
About
OriGen Biomedical, Inc. is a medical device company founded in 1997 by Richard Martin, with its headquarters located in Austin, Texas. The company specializes in developing and manufacturing products for cryopreservation and cell culture, primarily serving the medical and biotechnology sectors. OriGen Biomedical focuses on creating high-quality solutions to support patient health, particularly in areas such as cell therapy and regenerative medicine. Business/Product Breakdown OriGen Biomedical, Inc. designs and manufactures a range of cryopreservation and cell culture products tailored for applications in cell therapy, regenerative medicine, and bioprocessing. Its cryopreservation portfolio includes specialized bags and containers for the storage and transport of biological materials at ultra-low temperatures, ensuring the viability of cells and tissues. The company also offers cell culture products, such as permeable support systems and accessories, to facilitate the growth and maintenance of cells in controlled environments. All products are developed with a focus on quality, adhering to ISO 13485 and Medical Device Single Audit Program (MDSAP) certifications, and are subject to regular audits to meet regulatory and customer standards. OriGen's solutions are used by healthcare providers, research institutions, and biotechnology companies to advance patient care and therapeutic outcomes.
Financials
Revenue & Profit
Valuation
Ratios
People
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
Keywords
Keywords
Classified
Private